May 13, 1999
AMERIPATH ACQUIRES PATHOLOGY PRACTICES

Riviera Beach, FL, May 13, 1999 -- AmeriPath, Inc. (Nasdaq: PATH), a physician group practice focused on anatomic pathology services, continues to build on its Florida regional business model by announcing the acquisition of Hialeah and South Florida Pathology. The practice had annualized net revenues of $3.5 million in 1998. Terms of the transaction were not disclosed.

This acquisition increases the total number of practices to 12 in the state of Florida. Hialeah and South Florida Pathology, managed by Christopher G. Economides, M.D., located in Hialeah, Florida, provides service to the physician community of Hialeah Hospital and pathology services under a contract with SmithKline Beecham Clinical Laboratories (SBCL) for the three South Florida counties.

"This latest acquisition helps us to continue our leadership position and develop our regional business model in the state of Florida," said James C. New, President and CEO of AmeriPath, Inc. "AmeriPath is pleased to announce its association with Dr. Economides and we're proud to have him as a part of the AmeriPath team." Mr. New added, "This transaction not only strengthens our existing relationship with SBCL, but increases our presence in the South Florida/Dade County market."

AmeriPath, Inc. is the nation's leading physician group practice and laboratory management company focused on providing anatomic pathology services to physicians, hospitals, national clinical laboratories and managed care organizations. The Company presently operates in ten states and employs 231 pathologists who provide medical services through outpatient pathology laboratories, hospital inpatient laboratories and outpatient surgery centers.

.......................................................................................................................

This release contains certain forward-looking statements regarding AmeriPath, including its operations and prospects. Past performance is not necessarily indicative of future results. In addition, AmeriPath's actual results could differ materially from the results anticipated in these forward-looking statements as a result of uncertainties, including risks relating to demand, pricing, government regulation, payments and reimbursement, changes on reimbursement coding guidelines, dependence upon contracts and pathologists, acquisitions, integration of acquired practices, the market for pathology services, competition, and other factors identified in AmeriPath's filings with the Securities and Exchange Commission.